Loading
EMBioSys
EMBioSys is developing Efinia, a washable tank top that delivers a low-intensity electric field to breast tumours at home. It is an investigational device and has not been cleared by the FDA.
Also called: EMBIOSYS INC.EMBioSys Inc.
Overview
EMBioSys develops low-intensity induced electric field therapy (iEF therapy) delivered by Efinia, an electrode-free, battery-powered tank-top garment intended for use at home, aimed initially at breast cancer during the wait for surgery. The device is investigational and not FDA cleared. In fiscal year 2026 NCI awarded it USD 870,482 under SBIR award 5R44CA310518-02 for CuRrEnT, a study of capecitabine with the wearable device in triple-negative breast cancer with residual cancer burden after neoadjuvant treatment.
Headquarters
North Andover, MA, US
Scorecard
All companies#765of 1706 companies, score 2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 5R44CA310518-02: CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer | 2026 | $870K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Startup
Website
Products
1Wearable induced electric field device
Efinia is an experimental wearable device from EMBioSys, a tank top that sends a weak electric field into breast tumours at home. It is not FDA cleared.
Notes
- Read on embiosys.com and NIH RePORTER on 4 November 2026.
Connected
3cancers
fronts
Devices and software
Wearable induced electric field device
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
embiosys.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/